Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically documented ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma that has recurred \> 6 months after platinum-based chemotherapy
This must be the first recurrence of the epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma
Are at least two weeks but no more than 3 months after the completion of second-line cytotoxic chemotherapy
Are currently under observation or being treated with bevacizumab as a second-line maintenance therapy
Have a valid email address and access to the internet
Provide voluntary written informed consent
Speak and read English fluently
You may not be if
Current participation in a blinded clinical trial for ovarian cancer treatment. (Participation in a trial involving only supportive care medicines and/or growth factors is acceptable)
Another primary diagnosis of cancer in a different site
Clareo Health | Patient Reported Symptoms in Ovarian Cancer (PRECISION)
